ABVC · XBRL financial data

ABVC BioPharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ABVC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	483	356	970	152	510	—
Cost of revenue	19	5	286	302	1	—
Gross profit	464	351	683	(150)	509	—
Research and development	550	1,004	2,693	1,063	179	121
Selling, general and administrative	4,273	5,746	6,068	5,368	2,261	2,887
Total operating expenses	8,970	12,057	15,798	8,067	5,214	7,151
Operating income (loss)	(8,506)	(11,706)	(15,114)	(8,217)	(4,705)	(7,151)
Interest income	71	43	188	185	87	167
Interest expense	405	227	294	2,493	826	416
Other income (expense)	175	22	(400)	3	134	(14)
Income tax expense (benefit)	(220)	825	798	256	(111)	24
Net income (loss)	(10,594)	(12,036)	(16,423)	(10,516)	(4,903)	(7,909)
Earnings per share, basic USD per share	(0.50)	(0.51)	(0.52)	(2.43)	(0.42)	(0.39)
Earnings per share, diluted USD per share	(0.50)	(0.51)	(0.50)	(2.43)	(0.42)	(0.39)
Weighted average shares, basic thousands of shares	19,716	25,054	31,665	4,336	11,674	20,109
Weighted average shares, diluted thousands of shares	19,716	25,054	30,153	4,336	11,674	20,109

Fiscal years (ABVC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	4,273	5,829	85	60	248	681
Short-term investments	—	108	76	79	65	64
Accounts receivable	160	281	98	2	—	—
Inventory	—	26	—	—	—	—
Prepaid and other current assets	172	528	150	101	96	347
Total current assets	6,173	9,625	2,987	1,657	2,180	2,501
Property and equipment, net	515	526	574	7,969	511	12,835
Right-of-use asset	1,773	1,472	1,161	809	640	1,913
Total assets	11,607	13,698	9,855	14,493	7,540	21,062
Accounts payable	23	—	—	—	—	—
Accrued liabilities	2,119	1,301	2,910	3,696	—	—
Total current liabilities	4,844	3,692	5,820	5,932	6,557	6,164
Lease liability, non-current	1,457	1,125	792	407	237	1,601
Total liabilities	8,945	4,828	6,619	6,362	6,816	7,765
Accumulated deficit	(25,642)	(38,481)	(54,904)	(65,420)	(68,950)	(76,858)
Total stockholders' equity	3,438	8,844	3,099	8,388	1,226	11,112
Total liabilities and equity	11,607	13,698	9,855	14,493	7,540	21,062
Common shares outstanding (cover page) thousands of shares	24,421	30,307	33,081	10,560	15,778	25,440

Fiscal years (ABVC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(10,594)	(12,036)	(16,423)	(10,516)	(4,903)	(7,909)
Stock-based compensation	4,147	5,307	7,037	1,636	2,773	4,143
Depreciation and amortization	—	12	24	—	—	—
Net cash from operating activities	(5,541)	(7,598)	(7,398)	(4,236)	(1,809)	(2,986)
Purchases of property and equipment	—	18	120	21	—	—
Net cash from investing activities	751	(806)	(1,722)	(360)	—	(1,209)
Proceeds from issuing common stock	7,615	11,119	3,664	1,050	—	—
Proceeds from long-term debt	—	236	—	—	—	—
Net cash from financing activities	9,568	9,996	4,014	3,919	1,981	4,638
Net change in cash	4,841	1,564	(5,173)	(675)	147	463

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Karyopharm Therapeutics	54,980	33,432	(24,931)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
BriaCell Therapeutics	9,852	not reported	(5,959)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Annovis Bio	18,729	0*	(21,914)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.